Navigation Links
At Twelve Months Post-Launch, the Majority of Surveyed Oncologists Have Prescribed Xtandi to Their Docetaxel-Pretreated Metastatic Castrate-Resistant Prostate Cancer Patients
Date:12/9/2013

EXTON, Pa., Dec. 9, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at 12 months following the U.S. launch of Medivation/Astellas Pharma's Xtandi for docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC), the majority of surveyed oncologists stated that they have prescribed Xtandi in clinical practice, whereas the majority of surveyed urologists indicated that they had not yet prescribed Xtandi. Of current non-prescribers who plan on prescribing Xtandi for docetaxel-pretreated mCRPC in the future, the majority of urologists and oncologists stated that they will prescribe Xtandi within the next six months.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The third wave of the LaunchTrends® Xtandi (US) report series—fielded 12 months following the launch of Xtandi for docetaxel-pretreated mCRPC in the United States—finds that surveyed physicians indicated that the lack of steroid requirement and the efficacy profile of Xtandi are among its top perceived advantages compared with Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga, a finding that is consistent with prior waves of research. Nearly one-quarter of surveyed physicians indicated that they perceive no disadvantage of Xtandi compared with Zytiga.

The report also finds that the majority of surveyed physicians stated that first-line use of Zytiga for the treatment of chemotherapy-naive mCRPC remains unchanged following the commercial availability of Xtandi in the docetaxel-pretreated mCRPC setting. According to surveyed oncologists, Zytiga is currently the first-line patient share leader for the treatment of chemotherapy-naive mC
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InspireMDs MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
2. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
3. LDM Group and Polyglot Systems Partnership Brings Easy-to-Understand Medication Instructions to Over Twelve Languages
4. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
5. International Isotopes Inc. Announces Third Quarter And Nine Months 2013 Financial Results
6. Skyline Medical Announces Results for Third Quarter and First Nine Months of 2013
7. China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2013
8. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
9. The Majority Of Oncologists Will Begin Using Biosimilar Monoclonal Antibodies Within 12 Months Of Launch
10. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
11. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/1/2015)... ... 01, 2015 , ... According to a study published August 25th ... participated in a three year study about weight loss and diabetes were far more ... weight loss surgery at the onset of the trial. In fact, the participants in ...
(Date:9/1/2015)... New York, NY (PRWEB) , ... September 01, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – today announced its annual Light it Red for Lymphoma awareness ...
(Date:9/1/2015)... ... 01, 2015 , ... Celebrity hairstylist and Beauty Gives Back Art Team member ... Fashion” on Thursday, Oct. 1, at the La Valencia Hotel. The presentation, on the ... between fashion and professional hair, makeup and nail design. , The evening of ...
(Date:9/1/2015)... Seattle, WA (PRWEB) , ... September 01, 2015 , ... ... despite increasing awareness of societal issues and needs. Money for Good 2015, released today ... for solving it. There’s an annual potential to mobilize up to $22B in new ...
(Date:9/1/2015)... ... ... Georgia State University and its partners have introduced a ... assaults on their campuses. , The free, evidence-based survey was developed by the ... student affairs professionals responding to calls by the Obama Administration to strengthen efforts ...
Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2
... ... Shelton, O’Leary & Peterson, LLC, has been appointed to the Plaintiffs, Steering Committee in the ... ... partner with Onder, Shelton, O’Leary & Peterson, LLC, was appointed by U.S. District Judge David ...
... , , BOSTON, Nov. 14 Joslin ... care organization, has completed a major overhaul of its ... for patients, researchers, healthcare professionals and the public. , ... Joslin.org website," said Michael Sullivan, Senior Vice President for ...
... of senior athletes finds better density with some sports, ... sports might help boost bone mineral density in mature ... male and female athletes, aged 50 to 93, who ... Pittsburgh, including 560 who competed in high-impact sports such ...
... ... shipping. , ... 2009 -- Medical scrubs begin to look worn more quickly than other clothing items and ... every year. If you are looking for a great place to purchase scrubs, blue ...
... , WASHINGTON, Nov. 14 ... Bureau: , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) , ... Profile America -- Saturday, November 14th. Each year, ... the public aware of the serious nature of the disease, and ...
... ... Claims and Practices of Mind Control Cult. Inspired by numerous responses to ... second book, AMORC Unmasked! This book goes into greater depth, exposing the ... Crucis, commonly called AMORC, but also defending the possibility for a true ...
Cached Medicine News:Health News:Federal Court Appoints Onder Law Firm Partner as Co-Lead Counsel to the Plaintiffs' Steering Committee of the Multi-District Litigation for Yasmin and Yaz Litigation 2Health News:Federal Court Appoints Onder Law Firm Partner as Co-Lead Counsel to the Plaintiffs' Steering Committee of the Multi-District Litigation for Yasmin and Yaz Litigation 3Health News:High-Impact Activity May Be Good for Old Bones 2Health News:blue sky scrubs adds Caribbean Blue Scrubs 2Health News:Pierre S. Freeman Adds Book AMORC Unmasked! To his Arsenal of Whistleblower Weapons Aimed at Rosicrucian Order 2Health News:Pierre S. Freeman Adds Book AMORC Unmasked! To his Arsenal of Whistleblower Weapons Aimed at Rosicrucian Order 3
... The SeedVac™ is a vacuum driven device designed to ... tube tip. Seeds are drawn into the clear tube ... the hand piece to create the vacuum. The prescribed ... the clear tube tip before being placed into the ...
MT-BT-5001-25 prostate seeding needle (set of 25 unloaded needles).,MT-BT-5001-P prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seeding...
... a myoma was performed with a cutting ... vaporization of myomas with the VaporTrode Vaporization ... tissue chips that obscure visibility. No tissue ... This unique design provides areas of high ...
... The 19 Fr. OES 4000 Nephroscope, with ... quality with outstanding durability. The lumbotome, for ... the telescopic bougies, allow safer access. The ... comprehensive range of grasping forceps and lithotripsy ...
Medicine Products: